CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 2, 1996, Pages 128-136

  Ratto, Silvia ^a   Sitz, Karl V ^b   Scherer, Aimée M ^a   Loomis, Lawrence D ^a   Cox, Josephine H ^c   Redfield, Robert R ^d   Birx, Deborah L ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c SRA Technologies Inc   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

CD4+ T lymphocyte; Epitope; HIV 1; V3 loop

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030021112     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199602010-00003     Document Type: Article

References (46)

1. Ivanoff LA, Looney DJ, McDanal C, et al. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res Hum Retroviruses 1991;7:595-603.
2. Phillips RE, Rowland JS, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition [Comments]. Nature 1991;354:453-9.
3. Williams KJ, Loeb LA. Retroviral reverse transcriptases: error frequencies and mutagenesis. Curr Top Microbiol Immunol 1992;176:165-80.
4. Wain HS. The fastest genome evolution ever described: HIV variation in situ. Curr Opin Genet Dev 1993;3:878-83.
5. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992;257:217-9.
6. Lefebvre JC, Giordanengo V, Doglio A, et al. Altered sialylation of CD45 in HIV-1-infected T lymphocytes. Virology 1994;199:265-74.
7. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev 1992;3:173-93.
8. Shearer GM, Clerici M. T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Chem Immunol 1992;54:21-43.
9. Cann AJ, Churcher MJ, Boyd M, et al. The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism. J Virol 1992;66:305-9.
10. Cordonnier A, Montagnier L, Emerman M. Single aminoacid changes in HIV envelope affect viral tropism and receptor binding. Nature 1989;340:571-4.
11. Eiden LE, Lifson JD. HIV interactions with CD4: a continuum of conformations and consequences. Immunol Today 1992;13:201-6.
12. Hoffenbach A, Langlade DP, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 1989;142:452-62.
13. Koup RA, Pikora CA, Mazzara G, Panicali D, Sullivan JL. Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol 1991;4:215-23.
14. Pinching AJ. Antibody responses in HIV infection [Editorial; comment]. Clin Exp Immunol 1991;84:181-4.
15. Ahearne PM, Matthews TJ, Lyerly HK, White GC, Bolognesi DP, Weinhold KJ. Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988;4:259-67.
16. Dadaglio G, Leroux A, Langlade DP, et al. Epitope recognition of conserved HIV envelope sequences by human cytotoxic T lymphocytes. J Immunol 1991;147:2302-9.
17. Johnson RP, Trocha A, Buchanan TM, Walker BD. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med 1992;175:961-71.
18. Johnson RP, Trocha A, Buchanan TM, Walker BD. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 1993;67:438-45.
19. Moore JP, Nara PL. The role of the V3 loop of gp120 in HIV infection. AIDS 1991;5:21-33.
20. Matsushita S, Robert GM, Rusche J, et al. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988;62:2107-14.
21. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-6.
22. Bergeron L, Sullivan N, Sodroski J. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J Virol 1992;66:2389-97.
23. Freed EO, Myers DJ, Risser R. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol 1991;65:190-4.
24. Clerici M, Lucey DR, Zajac RA, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991;146:2214-9.
25. Takahashi H, Nakagawa Y, Pendleton CD, et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 1992;255:333-6.
26. Takahashi H, Houghten R, Putney SD, et al. Structural requirements for class IMHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J Exp Med 1989;170:2023-35.
27. Clerici M, Stocks NI, Zajac RA, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989;339:383-5.
28. + T-lymphocyte lines from HIV-1 seropositive patients. J Infect Dis 1995;171:1420-30.
29. + CTL in vivo with peptide vaccine constructs. J Immunol 1994;152:549-56.
30. Stuhler G, Waiden P. Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol 1993;23:2279-86.
31. Takahashi H, Merli S, Putney SD, et al. A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. Science 1989;246:118-21.
32. Takahashi H, Germain RN, Moss B, Berzofsky JA. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J Exp Med 1990;171:571-6.
33. + A24-restricted cytotoxic T lymphocytes. J Virol 1992;66:3151-4.
34. Muesing MA, Smith DH, Cabradilla CD, Benton CV, Lasky LA, Capon DJ. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985;313:450-8.
35. Myers G, Wain-Hobson S, Korber B, Smith RF, Pavlakis GN. Human retrovimses and AIDS. Los Alamos, NM: Theoretical Biophysics Group, Los Alamos National Laboratory, 1993.
36. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992;8:1887-95.
37. Javaherian K, Langlois AJ, La RG, et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 [published erratum appears in Science 1991;251(4989):13]. Science 1990;250:1590-3.
38. Berzofsky JA, Pendleton CD, Clerici M, et al. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. J Clin Invest 1991;88:876-84.
39. Billaud JN, Yagello M, Gluckman JC. Primary in vitro sensitization of human T-helper lymphocytes by peptides derived from the V3 loop of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein. Vaccine 1994;12:46-55.
40. Hammer J, Takacs B, Sinigaglia F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 1992;176:1007-13.
41. Guttinger M, Romagnoli P, Vandel L, et al. HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int Immunol 1991;3:899-906.
42. O'Sullivan D, Sidney J, Del GM, Colon SM, Sette A. Truncation analysis of several DR binding epitopes. J Immunol 1991;146:1240-6.
43. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
44. + cell depletion. Cell 1988;54:561-75.
45. + cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6. J Virol 1992;66:608-11.
46. + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-42.